QTTB News & Events

Q32 Bio announced a $10.5M registered direct offering. This transaction was led by a new institutional investor with participation by an existing dedicated public institutional investor. Q32 Bio has entered into a definitive agreement for the issuance and sale of 1.667M shares of common stock and pre-funded warrants to purchase up to 1.026M shares of common stock at an offering price of $3.90 per share of common stock, which was the closing price per share of Q32 Bio's common stock on Nasdaq on February 13 and $3.8999 per pre-funded warrant, which represents the price for the common stock less the $0.0001 per share exercise price for each pre-funded warrant. The pre-funded warrants will be immediately exercisable at a nominal exercise price of $0.0001 per share and may be exercised at any time until the pre-funded warrants are exercised in full. The closing of the offering is expected to occur on or about February 18, 2026, subject to the satisfaction of customary closing conditions. The gross proceeds to Q32 Bio from this offering are expected to be approximately $10.5M, before deducting certain offering expenses. Q32 Bio intends to use the net proceeds from the offering, together with its existing cash, cash equivalents and marketable securities, for working capital purposes including expenses related to research, clinical development and commercialization efforts including for supporting the advancement of bempikibart into future clinical trials for the treatment of alopecia areata.

Q32 Bio (QTTB) announced that it has sold its Phase 2 complement inhibitor, ADX-097, to Akebia Therapeutics (AKBA). Akebia has acquired ADX-097 and will be responsible for future development and commercialization. Under the terms of the agreement, Q32 Bio will receive $12 million in upfront payments and a near-term milestone, which includes $7 million received at signing, $3 million at the 6-month anniversary of signing, and $2 million payable upon the earlier of the achievement of a milestone or the end of 2026. These payments as well as potential development, regulatory and commercial milestones total up to $592 million. Q32 Bio is also eligible to receive tiered royalties on potential future sales of ADX-097, ranging from low single-digit to mid-teen percentages.

Akebia Therapeutics (AKBA) announced the establishment of its rare kidney disease pipeline. The pipeline is comprised of two core product candidates: ADX-097, a potential next generation complement inhibitor, now referred to as AKB-097, and praliciguat, a soluble guanylate cyclase stimulator. Akebia acquired all rights to AKB-097, a tissue-targeted C3d-Factor H fusion protein complement inhibitor, from Q32 Bio Inc. (QTTB) and believes AKB-097 has applicability across a wide range of complement-mediated rare kidney diseases. AKB-097 is targeted to the sites of complement activation in tissues and is not expected to result in systemic complement inhibition seen with other inhibitors. On November 28, 2025, Akebia and Q32 Bio signed an Asset Purchase Agreement under which Akebia acquired global rights to Q32 Bio's ADX-097. In consideration, Akebia paid Q32 Bio an upfront payment of $7M. Akebia will also make a $3M payment upon the six-month anniversary of the closing, as well as additional development and regulatory milestones, commercial milestones and tiered royalties on annual net sales of AKB-097.